Literature DB >> 15208656

Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.

Florence Armstrong1, Marie-Michèle Duplantier, Pascal Trempat, Corinne Hieblot, Laurence Lamant, Estelle Espinos, Claire Racaud-Sultan, Michèle Allouche, Elias Campo, Georges Delsol, Christian Touriol.   

Abstract

Majority of anaplastic large-cell lymphomas (ALCLs) are associated with the t(2;5)(p23;q35) translocation, fusing the NPM (nucleophosmin) and ALK (anaplastic lymphoma kinase) genes (NPM-ALK). Recent studies demonstrated that ALK may also be involved in variant translocations, namely, t(1;2)(q25;p23), t(2;3)(p23;q21), t(2;17)(p23;q23) and inv(2)(p23q35), which create the TPM3-ALK, TFG-ALK5, CLTC-ALK, and ATIC-ALK fusion genes, respectively. Although overexpression of NPM-ALK has previously been shown to transform fibroblasts, the transforming potential of variant X-ALK proteins has not been precisely investigated. We stably transfected the cDNAs coding for NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK or ATIC-ALK into nonmalignant NIH3T3 cells. All X-ALK variants are tyrosine phosphorylated and their subcellular distribution was in agreement with that observed in tumors. Moreover, our results show that the in vitro transforming capacity of NIH3T3-transfected cells are in relation to the level of X-ALK fusion proteins excepted for TPM3-ALK for which there is an inverse correlation. The differences between the five X-ALK variants with regard to proliferation rate, colony formation in soft agar, invasion, migration through the endothelial barrier and tumorigenicity seem to be due to differential activation of various signaling pathways such as PI3-kinase/AKT. These findings may have clinical implications in the pathogenesis and prognosis of ALK-positive ALCLs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208656     DOI: 10.1038/sj.onc.1207813

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

1.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

Review 2.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

3.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

4.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

5.  Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q.

Authors:  Tae-Min Kim; Seon-Hee Yim; Seung-Hun Shin; Hai-Dong Xu; Yu-Chae Jung; Cheol-Keun Park; Jong-Young Choi; Won-Sang Park; Mi-Seon Kwon; Heike Fiegler; Nigel P Carter; Mun-Gan Rhyu; Yeun-Jun Chung
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

6.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

7.  Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions.

Authors:  Maria K E Blixt; Stephen J Royle
Journal:  Traffic       Date:  2011-03-24       Impact factor: 6.215

8.  Looking for the functions of RNA granules in ALK-transformed cells.

Authors:  Mohamad Fawal; Estelle Espinos; Olivier Jean-Jean; Dominique Morello
Journal:  Bioarchitecture       Date:  2011-03

9.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.